Efficacy and safety of adalimumab in Crohn's disease: Meta‐analysis of placebo‐controlled trials
Open Access
- 22 March 2011
- journal article
- research article
- Published by Wiley in Journal of Digestive Diseases
- Vol. 12 (3) , 165-172
Abstract
OBJECTIVE: To evaluate the efficacy and safety of adalimumab in inducing and maintaining remission of Crohn's disease. METHODS: Electronic databases were searched. Placebo‐controlled trials of adalimumab used in patients with Crohn's disease were included. Data were analyzed with Review Manager 4.2. RESULTS: Four studies enrolling 1402 patients were confirmed as meeting our criteria. Remission rates of inducing and maintaining remission in patients with Crohn's disease were higher for adalimumab than placebo (P < 0.05). Adalimumab significantly improves the quality of life in patients with Crohn's disease. No significant difference in total adverse events was found in maintaining remission. Moreover, there were significantly less serious adverse events from taking adalimumab than from taking the placebo in long‐term treatment. Patients with increased baseline C‐reactive protein may benefit more from adalimumab therapy than those without. CONCLUSIONS: Adalimumab is effective and safe in Crohn's disease. However, studies of a larger number of patients are still required for better assessing the safety profile of adalimumab.Keywords
This publication has 24 references indexed in Scilit:
- Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Long‐Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta‐Analysis of Placebo‐Controlled TrialsClinical Infectious Diseases, 2010
- Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesAnnals of the Rheumatic Diseases, 2009
- The use of adalimumab in the management of refractory Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2007
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?The Lancet, 1998
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996